Successful FDA inspection at Aurisco

Aurisco Pharmaceutical today announced that its manufacturing site in Badu, Tiantai has successfully passed a USFDA cGMP inspection, which lasted for 5 days , from March 17 to March 21,2025. The inspection conclusion is NAI (No Action Indicated).

The inspection proved the site is compliant with the principles and guidelines of current Good Manufacturing Practices (GMP) of FDA.